Status:
RECRUITING
ARON-2 Study-Multicentric International Retrospective Study
Lead Sponsor:
Matteo Santoni
Conditions:
Urothelial Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The ARON-2 study retrospectively analyze patients treated with pembrolizumab as first-line therapy in patients platinum-unfit or as second-line therapy in patients progressed after previous platinum-b...
Eligibility Criteria
Inclusion
- Patients aged \>18y
- Histologically confirmed diagnosis of UC of upper and/or lower urinary tract
- Histologically or radiologically confirmed metastatic disease
- Patients treated with at least one of the following:
- Treatment with pembrolizumab in patients progressed after previous platinum-based chemotherapy or as first-line therapy in patients platinum-unfit, and at least 1 cycle of pembrolizumab within the period from 1 January 2018 to 30 November 2021
- Treatment with enfortumab vedotin in patients progressed to previous platinum-based chemotherapy and anti-PD-1/PD-L1 inhibitor and at least 1 cycle of enfortumab vedotin within the period from June 1st 2022 to July 31st 2023
Exclusion
- Patients without histologically confirmed diagnosis of UC
- Patients without histologically or radiologically confirmed metastatic disease
Key Trial Info
Start Date :
February 17 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2027
Estimated Enrollment :
367 Patients enrolled
Trial Details
Trial ID
NCT05290038
Start Date
February 17 2022
End Date
September 30 2027
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ospedale di Macerata, UOC Oncologia
Macerata, Macerata, Italy, 62100